Conservacion de flores comestibles I: efecto de la atmósfera

Postprint (published version

An Evaluation of Landmark-Based Methods to Explore Tooth Score Morphology: A Case Study on Felids and Hyenids

Taphonomic studies aim to identify the modifying agents that intervene in bone assemblages found at archaeopaleontological sites. Carnivores may modify, accumulate, or scavenge skeletal parts inflicting tooth marks, including scores, on the cortical surface. Several works have studied tooth score morphology to discern which carnivore group modified the bone assemblages, achieving different results. In the present study, different methods based on the use of landmarks and semilandmarks have been tested to describe and analyze the score profile cross-sections of spotted and brown hyenas, leopards, and lions. According to our results, the already published seven-landmark method is useful in order to differentiate between carnivore species from different families (e.g., felids and hyenids). Meanwhile, felid species (e.g., leopards and lions) cannot be consistently distinguished using any of the methods tested here. In contrast, hyenid species can be morphologically differentiated. On the other hand, the use of semilandmarks does not generally improve morphological characterization and distinction, but low numbers of landmarks and the inclusion of the score’s deepest point might provide the best results when semi-automatic semilandmark models are preferred to avoid sampling biases.The grant IJC2020-043576-I funded by MCIN/AEI/10.13039/501100011033 and the “European Union NextGenerationEU/PRTR” has been awarded to M.C.A. The grant RYC2021-034813-I funded by MCIN/AEI/10.13039/501100011033 and the European Union “NextGenerationEU”/PRTR has been awarded to M.Á.M.-G. During the development of the present work, J.A. was funded by the Euskal Herriko Unibertsitatea [ESPDOC21/05]. L.A.C. is funded by the Spanish Ministry of Science, Innovation and Universities by an FPI Predoctoral grant PRE2019-089411 associated with project RTI2018-099850-B-I0

Evolution of Angiogenic Factors in Pregnant Patients with Breast Cancer Treated with Chemotherapy

Factors angiogènics; Quimioteràpia; EmbaràsFactores angiogénicos; Quimioterapia; EmbarazoAngiogenic factors; Chemotherapy; PregnancyHigh prevalence of placental-derived complications, such as preeclampsia and intrauterine growth restriction, has been reported in women with breast cancer (BC) treated with chemotherapy during pregnancy (PBC-CHT). Aim: To ascertain whether PBC-CHT is associated with an imbalance of angiogenic factors, surrogate markers for placental insufficiency, that could explain perinatal outcomes. Methods: Prospective study between 2012 and 2016 in a single institution. Soluble fms-like tyrosine kinase (sFlt-1), placental growth factor (PlGF), and soluble endoglin (sEng) in maternal blood were assessed throughout pregnancy in 12 women with BC and 215 controls. Results: Cancer patients were treated with doxorubicin-based regimes and with taxanes. Ten PBC-CHT (83%) developed obstetrical complications. At the end of the third trimester, significantly higher levels of sFlt-1; sFlt-1/PGF ratio, and sEng levels were observed in BC women as compared to controls. Moreover; there was a significant correlation between plasma levels of sFlt-1 and the number of chemotherapy cycles administered. Besides, more chemotherapy cycles correlated with lower birthweight and head circumference at birth. Conclusions: Women with BC treated during pregnancy showed an antiangiogenic state compatible with placental insufficiency. Angiogenic factors could be useful in the clinical obstetric management of these patients; although further studies will be required to guide clinical decision-making.This study was funded by the Spanish Research Project in Health funded by ISCIII, the state plan for scientific and technical research and innovation 2015–2018, and European Regional Development Fund (ERDF), ref. PI15/02252. This study was also supported in part by RETICS ‘Maternal and Child Health and Development Network’ (SAMID Network), funded by the PN I + D + i 2008–2016 (Spain), ISCIII-Sub-Directorate General for Research Assessment and Promotion, and the European Regional Development Fund (ERDF), ref. RD12/0026 and RD16/0022. O.S. was supported by SAMID Network (RD12/0026/0016 and RD16/0022/0015) and S.M. was supported by “Paseico de la mama”

Brain and immune system-derived extracellular vesicles mediate regulation of complement system, extracellular matrix remodeling, brain repair and antigen tolerance in Multiple sclerosis

Background: Multiple sclerosis (MS) is an immune-mediated central nervous system disease whose course is unpredictable. Finding biomarkers that help to better comprehend the disease's pathogenesis is crucial for supporting clinical decision-making. Blood extracellular vesicles (EVs) are membrane-bound particles secreted by all cell types that contain information on the disease's pathological processes. Purpose: To identify the immune and nervous system-derived EV profile from blood that could have a specific role as biomarker in MS and assess its possible correlation with disease state. Results: Higher levels of T cell-derived EVs and smaller size of neuron-derived EVs were associated with clinical relapse. The smaller size of the oligodendrocyte-derived EVs was related with motor and cognitive impairment. The proteomic analysis identified mannose-binding lectin serine protease 1 and complement factor H from immune system cell-derived EVs as autoimmune disease-associated proteins. We observed hepatocyte growth factor-like protein in EVs from T cells and inter-alpha-trypsin inhibitor heavy chain 2 from neurons as white matter injury-related proteins. In patients with MS, a specific protein profile was found in the EVs, higher levels of alpha-1-microglobulin and fibrinogen β chain, lower levels of C1S and gelsolin in the immune system-released vesicles, and Talin-1 overexpression in oligodendrocyte EVs. These specific MS-associated proteins, as well as myelin basic protein in oligodendrocyte EVs, correlated with disease activity in the patients with MS. Conclusion: Neural-derived and immune-derived EVs found in blood appear to be good specific biomarkers in MS for reflecting the disease state.This work was sponsored by a grant from Miguel Servet (CP20/00024 to Laura Otero-Ortega), Miguel Servet (CPII20/00002 to María Gutiérrez-Fernández), a predoctoral fellowship (FI18/00026 to Fernando Laso-García), a Río-Hortega grant (CM22/00065 to Gabriel Torres Iglesias and CM20/00047 to Elisa Alonso-López) and by Research Project (PI21/00918) from the Instituto de Salud Carlos III and co-funded by the European Union and by a grant CA1/RSUE/2021-00753 to Dolores Piniella funded by Ministerio de Universidades, Plan de Recuperación, Transformación y Resiliencia y la Universidad Autónoma de Madrid.S

Role of age and comorbidities in mortality of patients with infective endocarditis

[Purpose]: The aim of this study was to analyse the characteristics of patients with IE in three groups of age and to assess the ability of age and the Charlson Comorbidity Index (CCI) to predict mortality. [Methods]: Prospective cohort study of all patients with IE included in the GAMES Spanish database between 2008 and 2015.Patients were stratified into three age groups:<65 years,65 to 80 years,and ≥ 80 years.The area under the receiver-operating characteristic (AUROC) curve was calculated to quantify the diagnostic accuracy of the CCI to predict mortality risk. [Results]: A total of 3120 patients with IE (1327 < 65 years;1291 65-80 years;502 ≥ 80 years) were enrolled.Fever and heart failure were the most common presentations of IE, with no differences among age groups.Patients ≥80 years who underwent surgery were significantly lower compared with other age groups (14.3%,65 years; 20.5%,65-79 years; 31.3%,≥80 years). In-hospital mortality was lower in the <65-year group (20.3%,<65 years;30.1%,65-79 years;34.7%,≥80 years;p < 0.001) as well as 1-year mortality (3.2%, <65 years; 5.5%, 65-80 years;7.6%,≥80 years; p = 0.003).Independent predictors of mortality were age ≥ 80 years (hazard ratio [HR]:2.78;95% confidence interval [CI]:2.32–3.34), CCI ≥ 3 (HR:1.62; 95% CI:1.39–1.88),and non-performed surgery (HR:1.64;95% CI:11.16–1.58).When the three age groups were compared,the AUROC curve for CCI was significantly larger for patients aged <65 years(p < 0.001) for both in-hospital and 1-year mortality. [Conclusion]: There were no differences in the clinical presentation of IE between the groups. Age ≥ 80 years, high comorbidity (measured by CCI),and non-performance of surgery were independent predictors of mortality in patients with IE.CCI could help to identify those patients with IE and surgical indication who present a lower risk of in-hospital and 1-year mortality after surgery, especially in the <65-year group

Famílies botàniques de plantes medicinals

Facultat de Farmàcia, Universitat de Barcelona. Ensenyament: Grau de Farmàcia, Assignatura: Botànica Farmacèutica, Curs: 2013-2014, Coordinadors: Joan Simon, Cèsar Blanché i Maria Bosch.Els materials que aquí es presenten són els recull de 175 treballs d’una família botànica d’interès medicinal realitzats de manera individual. Els treballs han estat realitzat per la totalitat dels estudiants dels grups M-2 i M-3 de l’assignatura Botànica Farmacèutica durant els mesos d’abril i maig del curs 2013-14. Tots els treballs s’han dut a terme a través de la plataforma de GoogleDocs i han estat tutoritzats pel professor de l’assignatura i revisats i finalment co-avaluats entre els propis estudiants. L’objectiu principal de l’activitat ha estat fomentar l’aprenentatge autònom i col·laboratiu en Botànica farmacèutica

Peri-operative red blood cell transfusion in neonates and infants: NEonate and Children audiT of Anaesthesia pRactice IN Europe: A prospective European multicentre observational study

BACKGROUND: Little is known about current clinical practice concerning peri-operative red blood cell transfusion in neonates and small infants. Guidelines suggest transfusions based on haemoglobin thresholds ranging from 8.5 to 12 g dl-1, distinguishing between children from birth to day 7 (week 1), from day 8 to day 14 (week 2) or from day 15 (≥week 3) onwards. OBJECTIVE: To observe peri-operative red blood cell transfusion practice according to guidelines in relation to patient outcome. DESIGN: A multicentre observational study. SETTING: The NEonate-Children sTudy of Anaesthesia pRactice IN Europe (NECTARINE) trial recruited patients up to 60 weeks' postmenstrual age undergoing anaesthesia for surgical or diagnostic procedures from 165 centres in 31 European countries between March 2016 and January 2017. PATIENTS: The data included 5609 patients undergoing 6542 procedures. Inclusion criteria was a peri-operative red blood cell transfusion. MAIN OUTCOME MEASURES: The primary endpoint was the haemoglobin level triggering a transfusion for neonates in week 1, week 2 and week 3. Secondary endpoints were transfusion volumes, 'delta haemoglobin' (preprocedure - transfusion-triggering) and 30-day and 90-day morbidity and mortality. RESULTS: Peri-operative red blood cell transfusions were recorded during 447 procedures (6.9%). The median haemoglobin levels triggering a transfusion were 9.6 [IQR 8.7 to 10.9] g dl-1 for neonates in week 1, 9.6 [7.7 to 10.4] g dl-1 in week 2 and 8.0 [7.3 to 9.0] g dl-1 in week 3. The median transfusion volume was 17.1 [11.1 to 26.4] ml kg-1 with a median delta haemoglobin of 1.8 [0.0 to 3.6] g dl-1. Thirty-day morbidity was 47.8% with an overall mortality of 11.3%. CONCLUSIONS: Results indicate lower transfusion-triggering haemoglobin thresholds in clinical practice than suggested by current guidelines. The high morbidity and mortality of this NECTARINE sub-cohort calls for investigative action and evidence-based guidelines addressing peri-operative red blood cell transfusions strategies. TRIAL REGISTRATION: ClinicalTrials.gov, identifier: NCT02350348

Impact of COVID-19 on cardiovascular testing in the United States versus the rest of the world

Objectives: This study sought to quantify and compare the decline in volumes of cardiovascular procedures between the United States and non-US institutions during the early phase of the coronavirus disease-2019 (COVID-19) pandemic. Background: The COVID-19 pandemic has disrupted the care of many non-COVID-19 illnesses. Reductions in diagnostic cardiovascular testing around the world have led to concerns over the implications of reduced testing for cardiovascular disease (CVD) morbidity and mortality. Methods: Data were submitted to the INCAPS-COVID (International Atomic Energy Agency Non-Invasive Cardiology Protocols Study of COVID-19), a multinational registry comprising 909 institutions in 108 countries (including 155 facilities in 40 U.S. states), assessing the impact of the COVID-19 pandemic on volumes of diagnostic cardiovascular procedures. Data were obtained for April 2020 and compared with volumes of baseline procedures from March 2019. We compared laboratory characteristics, practices, and procedure volumes between U.S. and non-U.S. facilities and between U.S. geographic regions and identified factors associated with volume reduction in the United States. Results: Reductions in the volumes of procedures in the United States were similar to those in non-U.S. facilities (68% vs. 63%, respectively; p = 0.237), although U.S. facilities reported greater reductions in invasive coronary angiography (69% vs. 53%, respectively; p < 0.001). Significantly more U.S. facilities reported increased use of telehealth and patient screening measures than non-U.S. facilities, such as temperature checks, symptom screenings, and COVID-19 testing. Reductions in volumes of procedures differed between U.S. regions, with larger declines observed in the Northeast (76%) and Midwest (74%) than in the South (62%) and West (44%). Prevalence of COVID-19, staff redeployments, outpatient centers, and urban centers were associated with greater reductions in volume in U.S. facilities in a multivariable analysis. Conclusions: We observed marked reductions in U.S. cardiovascular testing in the early phase of the pandemic and significant variability between U.S. regions. The association between reductions of volumes and COVID-19 prevalence in the United States highlighted the need for proactive efforts to maintain access to cardiovascular testing in areas most affected by outbreaks of COVID-19 infection

Scienca lerneja kalendaro 2023 (esperanto)

El proyecto “Calendario Científico Escolar 2023” ha consistido en la elaboración de un calendario dirigido al alumnado de educación primaria y secundaria obligatoria. Cada día se ha recogido un aniversario científico o tecnológico como, por ejemplo, nacimientos de personas de estos ámbitos o conmemoraciones de hallazgos destacables. Además, el calendario se acompaña de una guía didáctica con orientaciones para el aprovechamiento educativo transversal del calendario en las clases, incluyendo actividades adaptadas a cada rango de edad y al alumnado con necesidades especiales. Se trata de la cuarta edición de este proyecto de divulgación científica.Proyecto FCT-21-17253 de la Fundación Española para la Ciencia y la Tecnología (FECYT); Agencia Estatal de Investigación (España); Ministerio de Ciencia e Innovación; Consejo Superior de Investigaciones Científicas; Universidad de León; Delegación del CSIC en Castilla y León; Instituto de Ganadería de Montaña (IGM, CSIC-ULE); Casa de la Ciència de Valencia (CSIC); Cátedra de Cultura Científica de la Universidad del País Vasco/ Euskal Herriko Unibertsitatea (UPV/EHU); People Help; University of California-Davis; Academia de la Llingua Asturiana; Federación Española de Esperanto; Teagasc; PuraVida Software; Universidad de Zaragoza; Casa Árabe; CSIC Delegació a Catalunya; CCULT.org; Museo Didáctico e Interactivo de Ciencias de la Vega Baja del Segura (MUDIC VBS-CV); Universidad Miguel Hernández; Unidade de Divulgación Científica e Cultural - Universidade da Coruña; Asociación Cultural Nogará Religada.Mujeres con Ciencia; Asociaţia Secular-Umanistă din România; Instituto Geológico y Minero de España (IGME); Centro de Biología Molecular Severo Ochoa (CSIC-UAM); Asociación Española para el Avance de la Ciencia (AEAC); Centro de Investigación del Cáncer (CIC, CSIC-USAL); Discapacitodos; Universitat de les Illes Balears (UIB); Comisión Mujeres y Ciencia de la Sociedad Geológica de España; Institut d’Investigació en Intel.ligéncia Artificial (IIIA-CSIC); Centre for Research in Agricultural Genomics (GRAG, CSIC-UAB-ICREA); Escuela de Estudios Hispano-americanos (CSIC); Institut Botànic de Barcelona (IIB, CSIC-Ajuntament Barcelona); Institut de Ciència de Materials de Barcelona (ICMAB, CSIC); Institut de Ciències del Mar (ICM, CSIC); PRISMA – Asociación para la diversidad afectivo-sexual y de género en ciencia, tecnología e innovación; Instituto de Recursos Naturales y Agrobiología de Salamanca (IRNASA, CSIC); Círculo Escéptico; Civiencia; Universidad Autónoma de Madrid; Escuela de Estudios Árabes (CSIC); Evento Ciencia; Europa Laica; Universidad de Oviedo; Institut de Microelectrònica de Barcelona - Centre Nacional de Microelectrònica (IMB-CNM, CSIC); Centre d'Estudis Avançats de Blanes (CEAB, CSIC).Peer reviewe

(farsi - فارسی‎) 2023 تقویم علمی مکتب

El proyecto “Calendario Científico Escolar 2023” ha consistido en la elaboración de un calendario dirigido al alumnado de educación primaria y secundaria obligatoria. Cada día se ha recogido un aniversario científico o tecnológico como, por ejemplo, nacimientos de personas de estos ámbitos o conmemoraciones de hallazgos destacables. Además, el calendario se acompaña de una guía didáctica con orientaciones para el aprovechamiento educativo transversal del calendario en las clases, incluyendo actividades adaptadas a cada rango de edad y al alumnado con necesidades especiales. Se trata de la cuarta edición de este proyecto de divulgación científica.Proyecto FCT-21-17253 de la Fundación Española para la Ciencia y la Tecnología (FECYT); Agencia Estatal de Investigación (España); Ministerio de Ciencia e Innovación; Consejo Superior de Investigaciones Científicas; Universidad de León; Delegación del CSIC en Castilla y León; Instituto de Ganadería de Montaña (IGM, CSIC-ULE); Casa de la Ciència de Valencia (CSIC); Cátedra de Cultura Científica de la Universidad del País Vasco/ Euskal Herriko Unibertsitatea (UPV/EHU); People Help; University of California-Davis; Academia de la Llingua Asturiana; Federación Española de Esperanto; Teagasc; PuraVida Software; Universidad de Zaragoza; Casa Árabe; CSIC Delegació a Catalunya; CCULT.org; Museo Didáctico e Interactivo de Ciencias de la Vega Baja del Segura (MUDIC VBS-CV); Universidad Miguel Hernández; Unidade de Divulgación Científica e Cultural - Universidade da Coruña; Asociación Cultural Nogará Religada .Mujeres con Ciencia; Asociaţia Secular-Umanistă din România; Instituto Geológico y Minero de España (IGME); Centro de Biología Molecular Severo Ochoa (CSIC-UAM); Asociación Española para el Avance de la Ciencia (AEAC); Centro de Investigación del Cáncer (CIC, CSIC-USAL); Discapacitodos; Universitat de les Illes Balears (UIB); Comisión Mujeres y Ciencia de la Sociedad Geológica de España; Institut d’Investigació en Intel.ligéncia Artificial (IIIA-CSIC); Centre for Research in Agricultural Genomics (GRAG, CSIC-UAB-ICREA); Escuela de Estudios Hispano-americanos (CSIC); Institut Botànic de Barcelona (IIB, CSIC-Ajuntament Barcelona); Institut de Ciència de Materials de Barcelona (ICMAB, CSIC); Institut de Ciències del Mar (ICM, CSIC); PRISMA – Asociación para la diversidad afectivo-sexual y de género en ciencia, tecnología e innovación; Instituto de Recursos Naturales y Agrobiología de Salamanca (IRNASA, CSIC); Círculo Escéptico; Civiencia; Universidad Autónoma de Madrid; Escuela de Estudios Árabes (CSIC); Evento Ciencia; Europa Laica; Universidad de Oviedo; Institut de Microelectrònica de Barcelona - Centre Nacional de Microelectrònica (IMB-CNM, CSIC); Centre d'Estudis Avançats de Blanes (CEAB, CSIC). ePeer reviewe